Infection of cats with Dirofilaria immitis causes seroconversion on antibody tests and pulmonary pathology, often without subsequent development of adult heartworms. Consistent administration of topical 10% imidacloprid-1% moxidectin has been shown to result in sustained plasma levels of moxidectin in cats after three to five treatments, a pharmacokinetic behavior known as “steady state”. To evaluate the ability of moxidectin at “steady state” to protect cats from subsequent infection with D. immitis, cats (n = 10) were treated with the labeled dose of topical 10% imidacloprid-1% moxidectin for four monthly treatments. Each cat was inoculated with 25 third-stage larvae of D. immitis 7, 14, 21, and 28 days after the last treatment; non-treated cats (n = 9) were inoculated on the same days, serving as infection controls. Blood samples were collected from each cat from 1 month prior to treatment until 7 months after the final inoculation and tested for antibody to, and antigen and microfilaria of, D. immitis. Measurement of serum levels of moxidectin confirmed steady state in treated cats. Cats treated with topical 10% imidacloprid-1% moxidectin prior to trickle inoculation of D. immitis L3 larvae throughout the 28 day post-treatment period remained negative on antibody and antigen tests throughout the study and did not develop gross or histologic lesions characteristic of heartworm infection. A majority of non-treated cats tested antibody positive by 3–4 months post infection (6/9) and, after heat treatment, tested antigen positive by 6–7 months post-infection (5/9). Histologic lesions characteristic of D. immitis infection, including intimal and medial thickening of the pulmonary artery, were present in every cat with D. immitis antibodies (6/6), although adult D. immitis were confirmed in only 5/6 antibody-positive cats at necropsy. Microfilariae were not detected at any time. Taken together, these data indicate that prior treatment with 10% imidacloprid-1% moxidectin protected cats from subsequent infection with D. immitis for 28 days, preventing both formation of a detectable antibody response and development of pulmonary lesions by either immature stages of D. immitis or young adult heartworms.

Coyotes (Canis latrans) are commonly infested with ticks, including Amblyomma americanum, the predominant vector of Ehrlichia chaffeensis and Ehrlichia ewingii; Dermacentor variabilis, an important vector of Rickettsia rickettsii; and Amblyomma maculatum, a major vector of Rickettsia parkeri, a spotted fever group (SFG) Rickettsia. To determine the degree to which coyotes are infected with or exposed to tick-borne bacterial disease agents, serum samples collected from coyotes in Oklahoma and Texas were tested for antibodies reactive to R. rickettsii, Ehrlichia canis, E. chaffeensis, E. ewingii, Borrelia burgdorferi, and Anaplasma phagocytophilum by indirect fluorescent antibody (IFA) testing or enzyme-linked immunosorbent assay (ELISA). Of the coyotes tested, 60% (46/77) and 64% (47/74) had antibodies reactive to R. rickettsii and E. chaffeensis, respectively, on IFA. Additionally, 5% (4/77) had antibodies reactive to E. canis, but not B. burgdorferi or A. phagocytophilum, on SNAP(®) 4Dx(®) ELISA; subsequent serologic analysis by plate ELISA using species-specific peptides revealed antibodies to E. ewingii, E. canis, and E. chaffeensis in 46% (23/50), 18% (9/50), and 4% (2/50) of serum samples, respectively. Taken together, these data indicate that coyotes in this region are commonly exposed to SFG Rickettsia and E. ewingii and that further consideration of coyotes as a component of the maintenance cycle for these pathogens may be warranted.

Background: Microfilaria (MF) testing is an essential part of canine heartworm diagnostics, and it is recommended by the American Heartworm Society that a MF test be performed in tandem with antigen testing on every dog, every year, regardless of prevention status or history. There are a variety of methods that can be used to detect MF in canine whole blood; however, these methods widely vary in their sensitivities as well as practical factors, including time investment and cost. Additionally, some MF tests offer the advantage of being quantitative or allowing for morphological or molecular species identification, while other tests should only be used qualitatively. Methods: The purpose of this study is to evaluate the quantitative and qualitative performance of MF tests, including the 20 μL count, wet mount, 9 μL and 40 μL hematocrit tubes, thin smear, thick smear, modified Knott test (MKT), and conventional polymerase chain reaction (PCR). Results: Qualitatively, there was little difference in the performance of the 20 μL count, wet mount, MKT, and PCR. The MKT and PCR are the optimal MF tests, as these perform most reliably for detecting positives even when the MF per milliliter is relatively low, and in most cases, these two methods also allow for species-level confirmation of the identity. However, PCR tends to be a very costly test, and both PCR and MKT require a greater degree of expertise and time investment to perform than other tests. Even the lowest performance tests, including the thin smear and hematocrit tube methods, can reliably detect MF at very high burdens; although, caution should be advised when using low reliability methods, since there is a greater likelihood of failing to identify MF-positive dogs. Conclusions: Microfilaria (MF) testing is an essential part of heartworm diagnosis and screening in dogs, and test selection should balance practical factors such as cost and time investment with the patient’s risk of infection based on prevention status and history, clinical signs, and antigen testing results. This approach to MF testing will help minimize cost while avoiding failure to detect MF in infected dogs, especially when MF burden is low. Graphical

Anaplasma bovis is primarily an infectious agent of ruminants, and has most commonly been reported in Asia, the Middle East, and Africa. Although the primary cause of human anaplasmosis is Anaplasma phagocytophilum, humans may rarely be infected by other Anaplasma spp. Human disease attributed to A. bovis has been occasionally reported, including an A. bovis-like agent in the United States. DNA of an A. bovis-like agent has been amplified from humans and the tick Dermacentor variabilis in the central region of the U.S., but larger prevalence studies among potential vectors or reservoir hosts in the U.S. have not been reported. The aim of this study was to evaluate the prevalence of A. bovis-like agent among D. variabilis and cattle in the Southcentral U.S. Previously extracted DNA from adult D. variabilis collected from Oklahoma (n = 38) and Kansas (n = 93), and blood of cattle from Oklahoma (n = 140) were tested by conventional PCR. Overall prevalence of A. bovis-like DNA within ticks was determined to be 3.1% (4/131), and all positive ticks originated from Oklahoma. Overall prevalence in bovine blood was determined to be 0% (0/140). These findings confirm the presence of an A. bovis-like agent, a potentially zoonotic pathogen, among ticks in the Southcentral U.S.; this agent is likely underrecognized and has been detected in parts of the U.S. that lie outside of the established geographic range for A. phagocytophilum. Further investigation and surveillance are necessary to elucidate possible reservoirs of A. bovis in the U.S., further evaluate the burden of human infection, and fully characterize genetic differences between the A. bovis-like agent detected in the U.S. and A. bovis in other regions of the world.

Vector-borne infections persist as a significant issue in both human and animal health. Many of the most common vector-borne infections in the USA, especially tick-borne infections, are known to be zoonotic, including Lyme disease, anaplasmosis, and ehrlichiosis, and these infections may also negatively impact the health of infected animals. Convenient patient-side assays for the detection of antibodies to Borrelia burgdorferi, Anaplasma spp., and Ehrlichia spp., and antigen of Dirofilaria immitis have allowed for the generation of robust and large-scale prevalence data in dogs. Data of similar scale and distribution are not available in cats, and most feline prevalence studies have evaluated a small sample size with limited geographic distribution. The objective of this study was to evaluate the prevalence of antibodies to B. burgdorferi, Anaplasma spp., and Ehrlichia spp., and D. immitis antigen among shelter cats across the USA, a population that is presumably at high risk for ectoparasitism and, consequently, exposure to vector-borne infections. In total, 2232 whole blood samples were collected from shelter cats across four regions of the USA—South, Northeast, Midwest, and West—and were evaluated using the Idexx SNAP^® 4Dx^® Test. Ectoparasites were also opportunistically collected from cats during blood collection and morphologically identified. The prevalence of at least one vector-borne infection was 2.60%, and the nationwide prevalence was 1.88% for B. burgdorferi, 0.54% for Anaplasma spp., 0.09% for Ehrlichia spp., and 0.55% for D. immitis. A total of 1120 ectoparasites were collected from 423 cats, including 27 ticks and 1093 fleas. Although the overall prevalence of the pathogens in this survey is relatively low, we observe that there is an increased exposure risk regionally for some agents, with geographic distributions in this study mostly coinciding with established human and canine distributions. Understanding these findings in an assumed non-protected population of cats allows us to extrapolate the risk to pet cats if they are not provided routine veterinary care, including a broad-spectrum parasite prevention program.